pre-IPO PHARMA

COMPANY OVERVIEW

Antengene Corporation is a clinical-stage biopharmaceutical company that focuses on introducing cutting-edge treatments, ranging from early-to-late stage development pipelines to mature brands, to China and other Asian markets. With clinical development and regulatory expertise as well as local market knowledge in Asia Pacific, Antengene collaborates with academic research institutions and leading biotech companies around the world on diseases with higher incidence and urgent needs in China and other Asia Pacific countries/regions.


LOCATION

  • Shanghai, , China
  • Shaoxing City, Zhejiang, China

  • THERAPEUTIC AREAS

  • Infectious Disease
  • Oncology

  • WEBSITE

    https://www.antengene.com


    CAREER WEBSITE

    https://www.antengene.com/responsibility.php


    SOCIAL MEDIA


    INVESTORS

    hg-capital qiming-venture-partners tf-capital tigermed


    PRESS RELEASES


    Nov 20, 2020

    Antengene Corporation, an Innovative Cancer Biotech Company, is Listed on the Main Board of the Hong Kong Stock Exchange


    Jul 19, 2020

    Antengene Corporation Closes US$97 Million Series C Financing to Support Ongoing Drug Development and Preparations for Potential Commercialization


    Jun 8, 2020

    Antengene Corporation Appoints Mr. Donald Lung as Chief Financial Officer


    Apr 13, 2020

    Antengene Corporation Appoints Former Celgene ANZ General Manager Thomas Karalis as Head of Asia Pacific Regions


    Jan 6, 2020

    Antengene Corporation Appoints Former Celgene China GM John Chin as Chief Business Officer


    For More Press Releases


    Google Analytics Alternative